Molecular Partners (NASDAQ:MOLN) & Lucid Diagnostics (NASDAQ:LUCD) Financial Survey

Lucid Diagnostics (NASDAQ:LUCD) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Risk & Volatility

Lucid Diagnostics has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Earnings & Valuation

This table compares Lucid Diagnostics and Molecular Partners”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71 million	41.04	-$58.01 million	($0.47)	-2.02
Molecular Partners	$5.65 million	30.72	-$74.41 million	($1.71)	-2.51

Lucid Diagnostics has higher earnings, but lower revenue than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Lucid Diagnostics and Molecular Partners, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1	0	4	0	2.60
Molecular Partners	1	1	2	0	2.25

Lucid Diagnostics presently has a consensus price target of $4.19, indicating a potential upside of 340.23%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 94.86%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Molecular Partners.

Profitability

This table compares Lucid Diagnostics and Molecular Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Molecular Partners	N/A	-68.36%	-54.82%

Summary

Lucid Diagnostics beats Molecular Partners on 11 of the 14 factors compared between the two stocks.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.